Strategic focus Evaluate operates at the intersection of information services and pharma forecasting, offering integrated solutions like Evaluate Pharma, Omnium, and CDMO Intelligence. This presents a strong cross-sell opportunity to clients seeking end-to-end market intelligence, development risk assessment, and manufacturing landscape insights.

Pharma growth trend With a primary customer base in biopharma and a revenue range of 1M to 10M, there is potential to scale upsell around advanced forecasting, real-world data analytics, and portfolio optimization as clients expand their pipelines and launch activities.

Strategic partnerships Recent collaborations (Inpart partnership, Solactive indexing, Norstella ecosystem) indicate a willingness to integrate with other data platforms and analytics providers. This opens doors for co-sell arrangements, data-sharing agreements, and enhanced analytics offerings to prospective pharma clients.

Awards and credibility Recognitions in AI breakthrough awards for Evaluate Omnium and AI-driven decision management bolster credibility. Leverage these awards in outreach to prospective customers emphasizing AI-powered forecasting and risk assessment as differentiators.

Operational scale A mid-size team (51-200 employees) with a broad tech stack including MATLAB, Power BI, ELK, and SQL enables flexible, rapid deployment of customized forecasting and consulting projects. This supports quick onboarding for CDMO Intelligence and bespoke consulting engagements to win new logos.